Diagnosis
Pemphigus vulgaris
A potentially life-threatening autoimmune, blistering disease affecting the skin and mucous membranes.
Etiology
Cause [bci]
The precise etiology is unknown
Genetic risk (association with certain HLA alleles)
Enviromental triggers:
Drugs: Penicilline, captopril, cephalosporin, pyrazolones, NSAIDs, thiols, rifampin
Emotional stress
Diet
Thermal burns
Ultraviolet rays
Virus (coxsackievirus, Herpesviridae family)
Pathophysiology [p7h][bci]
IgG autoantibodies directed against cell-adhesion molecules (desmogleins)
This causes keratinocytes to fall apart (acabtholysis) --> bullous dermatosis
Less common types of pemphigus [k9p]
Familial Benign Pemphigus
Linear IgA Dermatosis
Pemphigus Erythematosus
Pemphigus Foliaceus
Pemphigus Herpetiformis
Drug-Induced Pemphigus
IgA Pemphigus
Paraneoplastic Pemphigus
Complications [bci]
Secondary infections (sepsis is the most common cause of death in PV)
Other autoimmune diseases
Malignancy
Corticosteroid side effects: osteoporosis, hyperglycemia, insomnia, increased appetite, hypertension, edema, adrenal suppression, cataracts, and delayed wound healing
Epidemiology
Incidence per 100.000 [pyi][mce][y6b]
Symptoms & findings
Symptoms
Onychodystrophy, Paronychia, Subungual hematoma
Clinical findings
None listed.
Anamneses
None listed.
Localized findings
Approach
Blood test: blood count, electrolytes, hepatic and renal function, glycemia and glycated hemoglobin, vitamin D, lipids, serology for hepatitis B and C, syphilis and HIV,
Urine test; pregnancy
Chest X-ray
Bone densitometry
Biopsy with immunofluorescence (accurate diagnosis)
ELISA
Treatment
First line treatment: [p7h][bci][0i5]
Prednisone 40 to 100 mg/day depending on severity
If control is not achieved: Methylprednisolone (1 g/day IV) or dexamethasone (300 mg/day IV) pulse therapy
Rituximab anti-CD 20 antibody
Second line treatment: Steroid-sparing immunosuppressives (hypertension, diabetes mellitus, glaucoma, or osteoporosis)
Azathioprine 100-200 mg/day (1-3 mg/kg/day) orally, divided into two doses
Mycophenolate mofetil/sodium 2-3g/day, divided into two doses
Third line treatment:
Intravenous human immunoglobulin (IVIG) 0.4g/kg/day for five days
Plasmapheresis/immunoadsorption
Cyclophosphamide orally (1-3 mg/kg/day)
Dapsone 50-200mg/day
Methotrexate 10 to 20mg/week
Cyclosporine 3-5mg/kg/day
Anti-TNF-α
Antibiotics: if secondary infection, guided by culture of blood and skin samples
Topical treatment: Always adjuvant to systemic treatment
Corticosteroid creams
Tacrolimus
Antibiotic creams
Antiseptic solutions (potassium permanganate)
Differential diagnoses
Aphthous stomatitis, Behcet's disease, Bullous pemphigoid, Dermatitis herpetiformis, Ecthyma, Eczema, Epidermolysis bullosa, Erysipelas, Erythema multiforme, Herpes simplex, Herpes zoster, IgA Pemphigus, Impetigo, Lichen planus, Paraneoplastic pemphigus, Pemphigus erythematosus, Pemphigus foliaceus, Stevens-Johnson syndrome, Systemic lupus erythematosus
References
[1] Ingold CJ, Sathe NC, Khan MAB. Pemphigus Vulgaris. [Updated 2024 Mar 1]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK560860/
[2] Porro AM, Seque CA, Ferreira MCC, Enokihara MMSES. Pemphigus vulgaris. An Bras Dermatol. 2019 Jul 29;94(3):264-278.
[3] Hübner F, König IR, Holtsche MM, Zillikens D, Linder R, Schmidt E. Prevalence and age distribution of pemphigus and pemphigoid diseases among paediatric patients in Germany. J Eur Acad Dermatol Venereol. 2020 Nov;34(11):2600-2605.
[4] Langan SM, Smeeth L, Hubbard R, Fleming KM, Smith CJ, West J. Bullous pemphigoid and pemphigus vulgaris--incidence and mortality in the UK: population based cohort study. BMJ. 2008 Jul 9;337(7662):a180.
[5] Kridin K, Schmidt E. Epidemiology of Pemphigus. JID Innov. 2021 Feb 20;1(1):100004.
[6] Zhao L, Chen Y, Wang M. The Global Incidence Rate of Pemphigus Vulgaris: A Systematic Review and Meta-Analysis. Dermatology. 2023;239(4):514-522.
[7] http://emedicine.medscape.com/article/1064187; [Medscape]
[8] [Clinical Dermatology 4.th Edition by Weller, Hunter, Savin and Dahl]